Compound ID | 256

Update compound information

SRI-20864

Class: Folate synthesis inhibitor

Agent Type: Small molecule; Direct acting;
Spectrum of activity: Antimycobacterial
Mechanism of action: Folate synthesis inhibitor. Dihydrofolate reductase inhibitor
Target Pathogen: Active against Mycobacterium avium and Mycobacterium tuberculosis
Description: Barrow EW, Suling WJ, Seitz, LE, etc. Screening of new selective inhibitors for Mycobacterium avium DHFR. Poster F-734 44th-ICAAC 2004;206.
Institute where first reported: Oklahoma State Univ., Coll of Vet. Med., US; Southern Res. Inst., USA
Year first mentioned: 2004
Development status: Experimental
Reason dropped: These were presented in early stages of the work. They suggest other compounds in the series in development which better solubility and selectivity, it is likely, these were superseded.
Chemical structure(s):
Click here for structure editor
Molecular weight: 354.41
Iso. SMILES: CCOC1=CC(=C(C=C1)OC)NCC2=CN=C3C(=C2C)C(=NC(=N3)N)N
InChI Key: CRZVJULBIPRHRY-UHFFFAOYSA-N
Can. SMILES: CCOC1=CC=C(C(=C1)NCC2=C(C)C3=C(N)N=C(N)N=C3N=C2)OC
InChI: InChI=1S/C18H22N6O2/c1-4-26-12-5-6-14(25-3)13(7-12)21-8-11-9-22-17-15(10(11)2)16(19)23-18(20)24-17/h5-7,9,21H,4,8H2,1-3H3,(H4,19,20,22,23,24)
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/15954331
Guide to Pharmacology: SRI-20864
Citations:
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1280141/

  • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.